NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
|
|
- Kerrie Gilmore
- 5 years ago
- Views:
Transcription
1 NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: diagnosis and management of colorectal cancer 1.1 Short title Colorectal cancer 2 The remit The Department of Health has asked NICE: To prepare a clinical guideline on the diagnosis and management of patients with all stages of primary colorectal cancer. This excludes any population screening and surveillance of high-risk groups, including patients with a family history and patients with inflammatory bowel disease.' 3 Clinical need for the guideline 3.1 Epidemiology a) Colorectal cancer is the third most common cancer in the UK, with approximately 32,300 new cases diagnosed and 14,000 deaths in England and Wales each year. Around half of people diagnosed with colorectal cancer survive for at least 5 years after diagnosis. b) Occurrence of colorectal cancer is strongly related to age, with 83% of cases arising in people older than 60 years. It is anticipated that as our elderly population increases, colorectal cancer will increase in prevalence. Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 1 of 9
2 3.2 Current practice a) There are variations in: the management of locally advanced disease the management of patients presenting with stage 4 disease the management of symptomatic primary colorectal cancer the role of sequenced therapies combining surgery, ablation, chemotherapies and biological agents in advanced disease. b) Patients with poor performance status, who are therefore at a greater risk of treatment-related morbidity and mortality, are increasingly being considered for radical interventions. These interventions may be curative but their impact needs to be balanced against the overall prognosis of the patient. c) The costs of the radical therapies for colorectal cancer have increased significantly over the past decade, posing a major health economics challenge. d) A clinical guideline will help to address these issues and offer guidance on best practice. 4 The guideline The guideline development process is described in detail on the NICE website (see section 6, Further information ). This scope defines what the guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health. If we are to produce a high-quality guideline within the allotted time it will not be possible to cover the entire care pathway described by the remit (see section 2). Therefore we intend to focus on clinical issues: for which there is uncertainty or disagreement on best practice Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 2 of 9
3 that will have the most significant impact on the clinical service and on the management of patients with colorectal cancer that could improve health outcomes and/or make better use of health resources that could help to avoid unlawful discrimination and reduce health equalities. A list of the prioritised clinical questions has been developed using advice from the Guideline Development Group chair and clinical lead, attendees at the NICE colorectal cancer stakeholder workshop and registered stakeholders. We acknowledge that there will be some important topics that are not part of the final prioritised list. These will go on to a holding list for future consideration within any update, and the final guideline will make this clear to the reader. The areas that will be addressed by the guideline are described in the following sections. 4.1 Population Groups that will be covered a) Adults (18 years and older) with newly diagnosed adenocarcinoma of the colon. b) Adults with newly diagnosed adenocarcinoma of the rectum. c) Adults with relapsed adenocarcinoma of the colon. d) Adults with relapsed adenocarcinoma of the rectum. e) No patient subgroups needing special consideration have been identified Groups that will not be covered a) Patients with anal cancer. b) Children (younger than 18) with colorectal cancer. Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 3 of 9
4 c) Patients with primary or secondary lymphoma of colon and rectum. d) Patients with pure small cell carcinoma of colon and rectum. e) Patients with carcinoid tumours of colon and rectum. f) Patients with high grade neuroendocrine tumours of colon and rectum. g) Patients with adenocarcinoma with some neuroendocrine differentiation. h) Patients with gastrointestinal stromal tumours (GIST) or sarcoma of colon and rectum. 4.2 Healthcare setting a) Primary care. b) Secondary care. c) Tertiary care in cancer centres, and regional centres for specialties such as stenting, hepatic surgery, thoracic surgery, endorectal therapies, radiotherapy and ablation therapies. 4.3 Clinical management Key clinical issues that will be covered a) Effective diagnostic modalities in establishing a diagnosis of colorectal cancer in patients referred with suspicious symptoms (considering effectiveness of methods in terms of sensitivity and specificity). b) Tumour staging system for defining treatment at all stages of disease in patients with colorectal cancer. c) Effective diagnostic modalities in determining which patients with rectal cancer are suitable for local resection. Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 4 of 9
5 d) Second-line treatment for patients who have received first-line treatment for colorectal cancer and are a) stable or b) progressing. e) Curative treatment for patients with stage 1 or polyp cancer (such as TEMS, endoscopic mucosal resection, radical surgery or contact radiotherapy). f) Treatment for patients presenting as emergencies with the symptoms of colorectal cancer (such as radical surgery with curative intent, defunctioning stoma or endoscopic stenting). g) The sequence of local and systemic treatments in patients with locally-advanced colorectal cancer to achieve cure, prolong life without cure, or to improve quality of life (such as surgery, stenting, radiotherapy and chemotherapy). h) The sequence of local and systemic treatments in patients with synchronous metastatic disease to achieve cure, prolong life without cure, or to improve quality of life. i) Effectiveness of a) pre-operative radiotherapy and b) chemoradiotherapy in treating patients with rectal cancer. j) For patients with stage 2 and 3 rectal cancer, the indications for giving adjuvant chemotherapy after surgery. k) For patients with high-risk stage 2 colorectal cancer, the indications for giving adjuvant chemotherapy after surgery. l) The sequence of ablation, surgery, regional therapy and systemic therapy, to achieve cure or long-term survival in patients with apparently incurable metastatic disease. m) Imaging methods to determine the extent of metastases in patients with colorectal cancer. n) Clinical indications for performing liver metastasectomy in patients with colorectal cancer metastasized to the liver. Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 5 of 9
6 o) Clinical indications for performing extrahepatic metastasectomy in patients with colorectal cancer. p) Chemotherapy for patients with advanced and metastatic disease (update of NICE technology appraisal guidance 93). q) Methods and frequencies of follow up after potentially curative treatment for primary colorectal cancer. r) Methods and frequencies of follow up after potentially curative treatment for metastatic colorectal cancer. s) We think it is important that patient issues should be represented on the list of priority topics investigated by this guideline. What in your view are the information and support issues specific to patients with colorectal cancer and their carers/families that the guideline should focus on? Clinical issues that will not be covered a) Population screening. b) Surveillance of high-risk groups, including patients with a family history of colorectal cancer and patients with inflammatory bowel disease. 4.4 Economic aspects Developers will take into account both clinical and cost effectiveness when making recommendations involving a choice between alternative interventions. A review of the economic evidence will be conducted and analyses will be carried out as appropriate. The preferred unit of effectiveness is the quality-adjusted life year (QALY), and the costs considered will usually only be from an NHS and personal social services (PSS) perspective. Further detail on the methods can be found in 'The guidelines manual' (see Further information ). Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 6 of 9
7 4.5 Status Scope This is the consultation draft of the scope. The consultation dates are 18 February to 18 March Timing The development of the guideline recommendations will begin in May Related NICE guidance 5.1 Published guidance NICE guidance to be updated This guideline will update and replace the following NICE guidance. Irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer (review). NICE technology appraisal guidance 93 (2005). Available from Other related NICE guidance Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy terminated appraisal. NICE technology appraisal 150 (2008). See Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. NICE technology appraisal guidance 118 (2007). Available from Laparoscopic surgery for the treatment of colorectal cancer (review). NICE technology appraisal guidance 105 (2006). Available from Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer. NICE technology appraisal guidance 100 (2006). Available from Referral guidelines for suspected cancer. NICE clinical guideline 27 (2005). Available from Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 7 of 9
8 Improving supportive and palliative care for adults with cancer. Cancer service guidance (2004). Available from: Improving outcomes in colorectal cancers: manual update. Cancer service guidance (2004). Available from Selective internal radiation therapy for colorectal metastases in the liver. NICE interventional procedure guidance 93 (2004). Available from Radiofrequency ablation for the treatment of colorectal metastases in the liver. NICE interventional procedure guidance 92 (2004). Available from Capecitabine and tegafur uracil for metastatic colorectal cancer. NICE technology appraisal guidance 61 (2003). Available from Guidance under development NICE is currently developing the following related guidance (details available from the NICE website). Cetuximab for the first line treatment of metastatic colorectal cancer. NICE technology appraisal guidance. Publication expected April Irinotecan for the adjuvant treatment of colon cancer. NICE technology appraisal guidance. Publication date to be confirmed. Bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer. NICE technology appraisal guidance. Publication date to be confirmed. 6 Further information Information on the guideline development process is provided in: How NICE clinical guidelines are developed: an overview for stakeholders' the public and the NHS The guidelines manual. Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 8 of 9
9 These are available from the NICE website ( Information on the progress of the guideline will also be available from the NICE website ( Colorectal cancer draft scope for consultation 18 February to 18 March 2009 Page 9 of 9
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Malignant melanoma: assessment and management of malignant melanoma 1.1 Short title Malignant Melanoma 2 The remit The Department
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationClinical guideline Published: 1 November 2011 nice.org.uk/guidance/cg131
Colorectal cancer: diagnosis and management Clinical guideline Published: 1 November 2011 nice.org.uk/guidance/cg131 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationColorectal cancer: the diagnosis and management of colorectal cancer
Clinical Guideline Colorectal cancer: the diagnosis and management of colorectal cancer Full Guideline Update information Since original publication this guideline has been partially updated: July 2018:
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationAppendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments
Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Section Consultees Comments Action Objective Roche RCP RCP As far as capecitabine is concerned, the objective
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Gastrointestinal bleeding: the management of acute upper gastrointestinal bleeding 1.1 Short title Acute upper GI bleeding
More informationHorizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Ulcerative colitis: the management of ulcerative colitis Quality standard title: Ulcerative
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update 1 Guideline title Anxiety: management of generalised anxiety disorder in adults in primary, secondary and community care (update)
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationBowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer
Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer Based on findings from the National Bowel Cancer Audit Background How are patients diagnosed?
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationCosting report: Bladder cancer
Putting NICE guidance into practice Costing report: Bladder cancer Implementing the NICE guideline on bladder cancer (NG2) Published: February 2015 Updated September 2015 to update the unit cost of transurethral
More informationNICE guideline Published: 24 January 2018 nice.org.uk/guidance/ng83
Oesophago-gastric cancer: assessment and management in adults NICE guideline Published: 24 January 18 nice.org.uk/guidance/ng83 NICE 18. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic fatigue syndrome/myalgic encephalomyelitis: diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis in
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic kidney disease: early identification and management of adults with chronic kidney disease in primary and secondary
More informationNational Institute for Health and Clinical Excellence SCOPE. Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults
National Institute for Health and Clinical Excellence 1 Guideline title SCOPE Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults 1.1 Short title Rheumatoid arthritis 2
More informationGuideline scope Diverticular disease: diagnosis and management
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Diverticular disease: diagnosis and management The Department of Health in England has asked NICE to develop a clinical guideline on diverticular
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
Appendix B: Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE Post publication note: The title of this guideline changed during development. This scope was published before the guideline
More informationPrimary brain tumours and cerebral metastases workshop
Primary brain tumours and cerebral workshop 22.4.16 Summary of workshop group discussions on the content of the scope Scope section Title: Primary brain tumours and cerebral Who the guideline is for People
More informationThe NIHCE guidelines for the management of colorectal cancer
The NIHCE guidelines for the management of colorectal cancer Graeme Poston Chair Colorectal Cancer Guideline Development Group and Colorectal Cancer Quality Standards Committee National Institute of Health
More informationSingle Technology Appraisal (STA) Vismodegib for treating basal cell carcinoma [ID1043]
Single Technology Appraisal (STA) Vismodegib for treating basal cell carcinoma [ID1043] Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Motor neurone disease: the use of non-invasive ventilation in the management of motor neurone disease 1.1 Short title Motor
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta242
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first- line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
DRAFT NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary
More informationEvolution of Surgery: Role of the Surgeon in the Molecular and Technology Age. Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010
Evolution of Surgery: Role of the Surgeon in the Molecular and Technology Age Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010 Molecular mechanisms for cancer Prevention and screening Molecular
More informationOncological Treatment of Colorectal & Anal Cancer
Oncological Treatment of Colorectal & Anal Cancer Pathway of Care Kent & Medway Cancer Collaborative Publication date July 2018 Expected review date July 2019 Version number 10.0 Version status Final Table
More informationSingle Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV melanoma
Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE The management of faecal incontinence in adults 1.1 Short title Faecal incontinence 2 Background (a) (b) (c) The National Institute
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE. Coeliac disease: recognition, assessment and management of coeliac disease
Appendix B: NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 1 Guideline title SCOPE Coeliac disease: recognition, assessment and management of coeliac disease 1.1 Short title Coeliac disease 2 The remit
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Clinical guideline for the management of atrial fibrillation 1.1 Short title Atrial fibrillation 2 Background a) The National Institute
More informationManchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationAppendix C Summary form
National Institute for Health and Clinical Excellence Appendix C Sorafenib for advanced hepatocellular carcinoma Comment 1: the draft remit Appropriateness Patients with HCC have a poor prognosis, with
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
More informationCetuximab for the first-line treatment of metastatic colorectal cancer
Cetuximab for the first-line treatment of metastatic colorectal cancer Issued: August 2009 guidance.nice.org.uk/ta176 NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationNational Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)
National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Sickle cell acute episode: management of an acute painful sickle cell episode in hospital 1.1 Short title Sickle cell acute
More informationCOLORECTAL CANCER CASES
COLORECTAL CANCER CASES Case #1 Case #2 Colorectal Cancer Case 1 A 52 year-old female attends her family physician for her yearly complete physical examination. Her past medical history is significant
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA 118 Colorectal cancer (metastatic) - bevacizumab &
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psychosis and schizophrenia in children and young people: recognition and management 1.1 Short title Psychosis and schizophrenia
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationClinical Practice Guidelines
Clinical Practice Guidelines FOR THE PREVENTION, EARLY DETECTION AND MANAGEMENT OF COLORECTAL CANCER APPROVED BY Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal
More informationColorectal cancer. The diagnosis and management of colorectal cancer. Issued: December NICE clinical guideline 131. guidance.nice.org.
Colorectal cancer The diagnosis management of colorectal cancer Issued: December 2014 NICE clinical guideline 131 guidance.nice.org.uk/cg131 NICE has accredited the process used by the Centre for Clinical
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension 1.1 Short title Glaucoma 2 Background
More informationPriority setting at a national level NICE - England. Gillian Leng Deputy Chief Executive, NICE September 2016
Priority setting at a national level NICE - England Gillian Leng Deputy Chief Executive, NICE September 2016 Areas to cover The role of NICE in the UK health system General approach to appraising new drugs
More informationGuideline scope Hypertension in adults (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Hypertension in adults (update) This guideline will update the NICE guideline on hypertension in adults (CG127). The guideline will be
More informationFollow up The way ahead. John Griffith
Follow up The way ahead John Griffith Key Emerging Principles Risk stratified pathways of care Personalised care plan and treatment summary with a hand held record Information and education Remote monitoring
More informationSurgical Therapy of GEP-NET: An Overview
Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationSingle Technology Appraisal (STA/MTA) Avelumab for treating metastatic Merkel cell carcinoma
Single Technology Appraisal (STA/MTA) Avelumab for treating metastatic Merkel cell carcinoma Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note:
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationUpper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012
Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012 Version Control This is a controlled document please destroy all previous versions on receipt
More informationNHS. High dose rate brachytherapy for carcinoma of the cervix. National Institute for Health and Clinical Excellence. Issue date: March 2006
NHS National Institute for Health and Clinical Excellence Issue date: March 2006 High dose rate brachytherapy for carcinoma of Understanding NICE guidance information for people considering the procedure,
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationGuideline scope Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Stroke and transient ischaemic attack in over s: diagnosis and initial management (update) 0 0 This will update the NICE on stroke and
More informationUPDATE IN THE MANAGEMENT AND TREATMENT OF COLORECTAL CANCER. Edwin A. Empaynado, MD Advocare Colon and Rectal Surgical Specialists
UPDATE IN THE MANAGEMENT AND TREATMENT OF COLORECTAL CANCER Edwin A. Empaynado, MD Advocare Colon and Rectal Surgical Specialists WHAT IS COLON CANCER? WHAT CAUSES COLORECTAL CANCER? WHAT ARE THE RISK
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Nalmefene for reducing alcohol consumption in people with alcohol dependence Draft scope (pre-referral) Draft remit/appraisal
More informationA clinical study of metastasized rectal cancer treatment: assessing a multimodal approach
Med Oncol (2014) 31:839 DOI 10.1007/s12032-014-0839-1 ORIGINAL PAPER A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach Michaela Jung Annica Holmqvist Xiao-Feng Sun
More informationDiagnostics consultation document KRAS mutation testing of tumours in adults with metastatic colorectal cancer
National Institute for Health and Care Excellence Diagnostics consultation document KRAS mutation testing of tumours in adults with The National Institute for Health and Care Excellence (NICE) is producing
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary tract infection: diagnosis, treatment and long-term management of urinary tract infection in children 1.1 Short title
More informationUsing whole disease models to inform resource allocation decisions. Paul Tappenden Senior Research Fellow May 2010
Using whole disease models to inform resource allocation decisions Paul Tappenden Senior Research Fellow May 2010 Overview of fellowship Funded through NIHR PAS Fellowship What is the role and value of
More informationCOLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE
COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE PROFESSOR OF SURGERY & DIRECTOR, PROFESSIONAL DEVELOPMENT CENTRE J I N N A H S I N D H M E D I C A L U N I V E R S I T Y faisal.siddiqui@jsmu.edu.pk
More informationReferral Criteria for Direct Access Outpatient Colonoscopy or Computed Tomography Colonography
Referral Criteria for Direct Access Outpatient Colonoscopy or Computed Tomography Colonography 2019 Released 2019 health.govt.nz Citation: Ministry of Health. 2019. Referral Criteria for Direct Access
More informationTechnology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer Technology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476 NICE 2018. All
More informationGastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Summary form Single Technology Appraisal (STA) Pixantrone monotherapy for the treatment of relapsed or refractory Response to consultee and commentator
More informationCASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION
CASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION PROVIDED AS AN EDUCATIONAL SERVICE BY THE INSTITUTE FOR CONTINUING HEALTHCARE EDUCATION SUPPORTED BY AN EDUCATIONAL GRANT FROM GENENTECH LEARNING
More informationColon, or Colorectal, Cancer Information
Colon, or Colorectal, Cancer Information Definition Colon, or colorectal, cancer is cancer that starts in the large intestine (colon) or the rectum (end of the colon). Other types of cancer can affect
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationPancreatic Cancer in adults:
National Institute for Health and Care Excellence Version 1.0 Pancreatic Cancer in adults: diagnosis and management Appendix K 31 July 2017 Draft for Consultation Developed by the National Guideline Alliance,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Intravenous fluid therapy in adults in hospital Quality standard title: Intravenous fluid
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationColorectal Cancer. Mark Chapman. MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist
Colorectal Cancer Mark Chapman MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist Overview Epidemiology of colorectal cancer Adenoma carcinoma sequence Tumour diagnosis & staging Treatment
More informationNICE Single Technology Appraisal of cetuximab for the treatment of recurrent and /or metastatic squamous cell carcinoma of the head and neck
NICE Single Technology Appraisal of cetuximab for the treatment of recurrent and /or metastatic squamous cell carcinoma of the head and neck Introduction Merck Serono appreciates the opportunity to comment
More information